Trinity Biotech (TRIB) Receivables (2009 - 2025)

Trinity Biotech has disclosed Receivables across 17 years of filings, most recently posting $9.4 million for Q4 2025.

• Receivables for Q4 2025 came in at $9.4 million, down 30.96% year-over-year; the trailing twelve-month figure through Dec 2025 was $9.4 million (down 30.96% YoY), and the FY2025 annual result was $9.4 million, down 30.96% from the prior year.
• Receivables came in at $9.4 million for Q4 2025 at Trinity Biotech, down from $10.9 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $2.7 billion in Q4 2022 to a low of $1.4 million in Q4 2023.
• The 5-year median for Receivables is $15.2 million (2021), against an average of $162.5 million.
• Across the five-year window, Receivables jumped 90020.56% in 2022 and slumped 99.95% in 2023, its largest moves.
• Trinity Biotech's Receivables stood at $3.0 million in 2021, then surged by 90020.56% to $2.7 billion in 2022, then plunged by 99.95% to $1.4 million in 2023, then soared by 859.32% to $13.6 million in 2024, then plunged by 30.96% to $9.4 million in 2025.
• The last three Receivables figures came in at $9.4 million (Q4 2025), $10.9 million (Q2 2025), and $13.6 million (Q4 2024), per Business Quant data.